Developer docs
API playgroundTry for free, no card

Search company profiles

FabRx

Full company profile

uuid0007aic

Namestring
FabRx
Legal namestring
FABRX Ltd.
Websiteurl
fabrx.co.uk
Company typeenum
Private
Founded yearint
2014
Descriptiontext

FabRx is a UK-based pharmaceutical technology company that develops and commercializes the M3DIMAKER ecosystem for the on-site production of personalized medicines. Its hardware platform comprises the GMP-compliant M3DIMAKER 1 (single printhead) and M3DIMAKER 2 (multi-printhead) pharmaceutical 3D printers, supported by exchangeable printheads spanning Semi-Solid Extrusion (SSE), Fused Deposition Modelling (FDM), and Direct Powder Extrusion (DPE), as well as integrated quality-control accessories including a Near-Infrared sensor, pressure sensor, in-built balance, and traceability system. The company extends the platform beyond 3D printing into blister, capsule, and suppositories filling technologies, offering an end-to-end compounding automation stack for hospital and community pharmacies.

The business operates a hybrid revenue model combining hardware sales (M3DIMAKER 2 and enterprise solutions), recurring subscriptions for M3DIMAKER 1 (from €1999/month targeted at European pharmacies and hospitals), software licensing for M3DIMAKER Studio and the Hub & Spoke compliance tier, and professional services through its Pharma-ink formulation development offering. Go-to-market is executed via direct enterprise sales to pharmaceutical companies, CDMOs, and large research institutions, a direct European website channel for pharmacy and hospital customers, and a 2025 strategic channel partnership with Pete Pharma for U.S. compounding pharmacies. Software and AI capabilities are housed in a wholly-owned Spanish subsidiary, FABRX·AI (launched 2023), which builds M3DIMAKER Studio, M3DIFEEDBACK, and the M3DISEEN printability-prediction tool.

FabRx's customer base spans pharmaceutical companies (Pfizer, AstraZeneca), leading pediatric and oncology hospitals (Great Ormond Street Hospital, Gustave Roussy, Vall d'Hebron University Hospital, Erasmus MC, Hospital General Universitario Dr. Balmis), academic research institutions (UCL, Cambridge, Monash, Maryland, Montreal, Heidelberg), and government agencies including the U.S. Centers for Disease Control and Prevention and Fiocruz. The company is founder-owned with no disclosed institutional funding, operates subsidiaries in the UK (London HQ), Spain (Madrid), and the United States, and was recognized with the King's Award for Enterprise 2026 in Innovation.

Short descriptiontext

FabRx is a UK-based pharmaceutical technology company that develops GMP-compliant M3DIMAKER 3D printing systems and supporting software for personalized medicine production, serving hospital pharmacies, community pharmacies, pharmaceutical companies, and academic research institutions worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical 3D printing, personalized medicine, drug compounding automation, GMP pharmaceutical equipment, pharma manufacturing software
Industry4 codes
PRIMARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYIMAAACAD
Machine Control, Firmware & Print Management
Industrials, Manufacturing & Construction/3D Printing/3D Printing Software (CAD/CAM, Slicing, Simulation, Workflow)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Printing and Related Support Activities3231
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Printing Trades Machinery & Equipment3555
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Pharmaceutical 3D Printing Systems
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical 3D Printer Sales
TypeHardware Sales
Description

Sale of M3DIMAKER 1 and M3DIMAKER 2 pharmaceutical 3D printers to pharmacies, hospitals, and research institutions. Printers are GMP compliant and designed for personalized medicine production.

fabrx.co.uk
2Printer Subscription
TypeSubscription Recurring
Description

Monthly subscription model for M3DIMAKER 1 starting from €1999 per month, specifically targeting pharmacies and hospitals in Europe.

fabrx.co.uk
3Software Licensing
TypeSubscription Recurring
Description

M3DIMAKER Studio software licensing with two tiers: Studio for basic printer control and Pharma-ink management, and Hub & Spoke for enhanced regulatory compliance with secure VPN access and performance reports.

fabrx.co.uk
4Pharma-ink Development Services
TypeProfessional Services
Description

Flexible formulation development services from consultation to full formulation development and analysis, helping develop and optimise 3D printable formulations.

fabrx.co.uk
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1M3DIMAKER 1 - Single printhead pharmaceutical 3D printer subscription
ModelSubscriptionBilling cadenceMonthly
Notes

FROM €1999 per month. Special offer for pharmacies and hospitals, only available in Europe.

fabrx.co.uk
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1M3DIMAKER
Description

Pharmaceutical 3D printing ecosystem for personalized medicine production including M3DIMAKER 1 (single printhead) and M3DIMAKER 2 (multi-printhead) systems.

fabrx.co.uk
+4 more records
Core offering1 text field

FabRx develops and commercializes the M3DIMAKER ecosystem of GMP-compliant pharmaceutical 3D printers (single-printhead M3DIMAKER 1 and multi-printhead M3DIMAKER 2), control software, in-line quality control sensors, and Pharma-ink formulation services that enable pharmacies, hospitals, and pharmaceutical companies to produce personalized medicines and small-batch pharmaceuticals on-site. The platform supports multiple manufacturing modalities including 3D printing, blister filling, capsule filling, and suppository filling under a single integrated system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Auto-filling 10,000 capsules with personalized doses in one day
Product overview1 text field

FabRx is a pharmaceutical technology company offering the M3DIMAKER ecosystem, a unified platform comprising hardware (M3DIMAKER 1 and M3DIMAKER 2 pharmaceutical 3D printers), software (M3DIMAKER Studio and Hub & Spoke), and quality control accessories (Near Infrared Sensor, Pressure Sensor, Balance, Traceability). The company provides four distinct manufacturing technologies under one ecosystem: 3D Printing, Blister Filling, Capsule Filling, and Suppositories Filling. Supporting services include Pharma-ink Development for formulation optimization, AI-powered tools (M3DISEEN for printability prediction, M3DIFEEDBACK for patient feedback), and exchangeable printhead systems (SSE, FDM, DPE) for the M3DIMAKER 2. All products are GMP compliant and designed for personalized medicine production in pharmacies, hospitals, and clinical trial settings.

Product and service7 records
1M3DIMAKER 1
CategoryPharmaceutical 3D Printer Hardware
Description

Single printhead, GMP-compliant pharmaceutical 3D printer for research and small-batch manufacture of personalized medicines and medical devices for human and veterinary precision medicine and drug development. Available by monthly subscription (from €1,999/month) targeting European pharmacies and hospitals.

2M3DIMAKER 2
CategoryPharmaceutical 3D Printer Hardware
Description

Multi-printhead (3 printhead attachments) GMP-compliant pharmaceutical 3D printer capable of rapid polypill manufacture and higher-throughput, larger batch production of personalized medicines and medical devices. Targeted at pharmaceutical companies, CDMOs, and large research institutions.

3M3DIMAKER Studio Software
CategoryPharmaceutical 3D Printing Software
Description

Bespoke software developed by FABRX·AI that controls the M3DIMAKER ecosystem, enabling 3D model selection, parameter preparation, and printer control. Includes dose-library generator and user group management; protocols can be locked for quality assurance in clinical use, and Hub & Spoke capabilities add secure VPN access, protocol sharing, downloadable libraries, and performance reports.

4M3DISEEN
CategoryPharmaceutical AI Software
Description

AI-driven predicting tool that assesses 3D printability of pharmaceutical formulations. Takes drug, excipients, and proportions as input, predicts formulation printability, and provides recommended 3D printing parameters and dissolution insights. Currently focused on FDM and offered as an online tool.

5M3DIFEEDBACK
CategoryPatient Feedback Software
Description

Phone application designed to collect patient and carer feedback for clinical projects. Custom downloadable apps can be created for each clinical project to provide a user-friendly feedback experience.

6Pharma-ink Development Services
CategoryPharmaceutical Formulation Services
Description

Professional formulation development services ranging from consultation to full formulation development and analysis, including active ingredient characterization, 3D printing optimization, in vitro analysis, and small batch manufacture with clinical trial guidance. Helps customers develop and optimize 3D-printable pharmaceutical formulations.

7FABRX Syringe Preheater
CategoryPharmaceutical 3D Printing Hardware Accessory
Description

Hardware accessory introduced in January 2026 for the M3DIMAKER ecosystem, designed to revolutionize high-volume 3D printing applications by preheating syringes used in pharmaceutical 3D printing.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Strategic partnership to introduce pharmaceutical 3D printing technology to the U.S. compounding pharmacy market. Pete Pharma developed a pharmacy-first business model to reduce operational burden and improve workflow efficiency for independent pharmacies. The partnership combines Pete Pharma's market expertise with FabRx's M3DIMAKER technology (M3DIMAKER 1 for research and small-batch manufacturing, M3DIMAKER 2 for higher throughput) to modernize personalized medicine production through automation and enhanced customization capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding research institution and origin of FabRx technology. Co-founders Prof. Alvaro Goyanes and colleagues developed pharmaceutical 3D printing technology at UCL. Ongoing collaboration for research and development of personalized medicine solutions.

Strategic tierCoreTypeTechnology or Integration
Description

Subsidiary company launched in 2023 in Spain, focused on advanced software solutions for pharmaceutical 3D printing and automated drug dispensing. Develops M3DIMAKER Studio software, M3DIFEEDBACK app, and M3DISEEN AI prediction tool.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical company collaboration for personalized medicine development research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical company collaboration for personalized medicine research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical collaboration for pharmaceutical 3D printing applications in hospital pharmacy settings, including pediatric formulations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pediatric healthcare institution collaboration for child-friendly personalized medicines using 3D printing technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cancer research center collaboration for pharmaceutical 3D printing applications in oncology treatments.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Triastek is a Chinese pharmaceutical 3D printing company developing 3D-printed drug formulations and working with regulators (including FDA IND clearances). It is the most comparable direct competitor to FabRx in pharmaceutical 3D printing hardware and formulation services.

TypeDirect peer
Description

Aprecia is the pioneer of pharmaceutical 3D printing, holding the first FDA-approved 3D-printed drug (Spritam). Its ZipDose platform competes directly with FabRx's M3DIMAKER in producing personalized oral dosage forms for hospitals and pharmacies.

TypeDirect peer
Description

MB Therapeutics is a German pharmaceutical 3D printing startup focused on personalized medicine and printing of individualized dosage forms. It is a direct European competitor in pharmaceutical 3D printing technology.

4Laxxon Medical
TypeDirect peer
Description

Laxxon Medical develops 3D-printed pharmaceuticals with its SPID-Technology platform, focused on oral drug delivery and personalized dosing. Comparable to FabRx in target market (personalized oral dosage forms) and technology category.

5Inventia Healthcare
TypeEmerging player
Description

Inventia develops powder-based pharmaceutical 3D printing technology for personalized medicine and clinical/research applications. Comparable as an emerging specialist in pharma 3D printing but with narrower scope than FabRx's multi-technology platform.

TypeBroad incumbent
Description

Catalent is a major CDMO with capabilities in oral solid dose manufacturing and is exploring advanced drug delivery technologies. As a broad incumbent in pharma manufacturing services, it represents the consolidation target or large competitor FabRx may eventually compete against for hospital compounding contracts.

TypeBroad incumbent
Description

GEA supplies industrial processing equipment for pharmaceutical manufacturing, including equipment for solid dosage forms. As an industrial incumbent in pharma manufacturing equipment, it could enter the personalized 3D printing space and compete with FabRx for hospital pharmacy installations.

8Glatt Group
TypeBroad incumbent
Description

Glatt offers integrated solutions for pharmaceutical production including solid dosage form manufacturing equipment. It is comparable to FabRx as a provider of equipment used in pharmaceutical production, though with a much broader and more established industrial equipment portfolio.

TypeBroad incumbent
Description

Through its Patheon CDMO business, Thermo Fisher offers pharmaceutical development and manufacturing services including oral solid dose capabilities. As a broad incumbent in pharma services, it competes for hospital and CDMO contracts that FabRx's platform could also address.

TypeOthers
Description

Evonik is a global specialty chemicals company and supplier of pharmaceutical excipients, including materials used in 3D-printed drug formulations. It is a partner of FabRx (excipient supplier) and thematically adjacent as the materials backbone of pharmaceutical 3D printing ecosystems.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature14 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FabRx

Pharmaceutical 3D Printing Systemsfabrx.co.uk

FabRx is a UK-based pharmaceutical technology company that develops GMP-compliant M3DIMAKER 3D printing systems and supporting software for personalized medicine production, serving hospital pharmacies, community pharmacies, pharmaceutical companies, and academic research institutions worldwide.

What FabRx does

FabRx is a UK-based pharmaceutical technology company that develops and commercializes the M3DIMAKER ecosystem for the on-site production of personalized medicines. Its hardware platform comprises the GMP-compliant M3DIMAKER 1 (single printhead) and M3DIMAKER 2 (multi-printhead) pharmaceutical 3D printers, supported by exchangeable printheads spanning Semi-Solid Extrusion (SSE), Fused Deposition Modelling (FDM), and Direct Powder Extrusion (DPE), as well as integrated quality-control accessories including a Near-Infrared sensor, pressure sensor, in-built balance, and traceability system. The company extends the platform beyond 3D printing into blister, capsule, and suppositories filling technologies, offering an end-to-end compounding automation stack for hospital and community pharmacies.

The business operates a hybrid revenue model combining hardware sales (M3DIMAKER 2 and enterprise solutions), recurring subscriptions for M3DIMAKER 1 (from €1999/month targeted at European pharmacies and hospitals), software licensing for M3DIMAKER Studio and the Hub & Spoke compliance tier, and professional services through its Pharma-ink formulation development offering. Go-to-market is executed via direct enterprise sales to pharmaceutical companies, CDMOs, and large research institutions, a direct European website channel for pharmacy and hospital customers, and a 2025 strategic channel partnership with Pete Pharma for U.S. compounding pharmacies. Software and AI capabilities are housed in a wholly-owned Spanish subsidiary, FABRX·AI (launched 2023), which builds M3DIMAKER Studio, M3DIFEEDBACK, and the M3DISEEN printability-prediction tool.

FabRx's customer base spans pharmaceutical companies (Pfizer, AstraZeneca), leading pediatric and oncology hospitals (Great Ormond Street Hospital, Gustave Roussy, Vall d'Hebron University Hospital, Erasmus MC, Hospital General Universitario Dr. Balmis), academic research institutions (UCL, Cambridge, Monash, Maryland, Montreal, Heidelberg), and government agencies including the U.S. Centers for Disease Control and Prevention and Fiocruz. The company is founder-owned with no disclosed institutional funding, operates subsidiaries in the UK (London HQ), Spain (Madrid), and the United States, and was recognized with the King's Award for Enterprise 2026 in Innovation.

FabRx firmographics

Firmographics
Name
FabRx
Legal name
FABRX Ltd.
Website
https://fabrx.co.uk
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
FabRx is a UK-based pharmaceutical technology company that develops GMP-compliant M3DIMAKER 3D printing systems and supporting software for personalized medicine production, serving hospital pharmacies, community pharmacies, pharmaceutical companies, and academic research institutions worldwide.
Ownership category
akta.pro rank

FabRx industry classification

Industry
Product category
Pharmaceutical 3D Printing Systems
NAICS
Printing and Related Support Activities (3231), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Printing Trades Machinery & Equipment (3555), Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYHLACAKAM
Compounding Pharmacy & Sterile Prep Workflow Systems
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYIMAAACAD
Machine Control, Firmware & Print Management
Industrials, Manufacturing & Construction/3D Printing/3D Printing Software (CAD/CAM, Slicing, Simulation, Workflow)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical 3D printing
  • Personalized medicine
  • Drug compounding automation
  • GMP pharmaceutical equipment
  • Pharma manufacturing software

Where FabRx is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

FabRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical 3D Printer Sales: Sale of M3DIMAKER 1 and M3DIMAKER 2 pharmaceutical 3D printers to pharmacies, hospitals, and research institutions. Printers are GMP compliant and designed for personalized medicine production.
  2. Printer Subscription: Monthly subscription model for M3DIMAKER 1 starting from €1999 per month, specifically targeting pharmacies and hospitals in Europe.
  3. Software Licensing: M3DIMAKER Studio software licensing with two tiers: Studio for basic printer control and Pharma-ink management, and Hub & Spoke for enhanced regulatory compliance with secure VPN access and performance reports.
  4. Pharma-ink Development Services: Flexible formulation development services from consultation to full formulation development and analysis, helping develop and optimise 3D printable formulations.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyM3DIMAKER 1 - Single printhead pharmaceutical 3D printer subscription

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

FabRx product offering

Product offering

Core offering

FabRx develops and commercializes the M3DIMAKER ecosystem of GMP-compliant pharmaceutical 3D printers (single-printhead M3DIMAKER 1 and multi-printhead M3DIMAKER 2), control software, in-line quality control sensors, and Pharma-ink formulation services that enable pharmacies, hospitals, and pharmaceutical companies to produce personalized medicines and small-batch pharmaceuticals on-site. The platform supports multiple manufacturing modalities including 3D printing, blister filling, capsule filling, and suppository filling under a single integrated system.

Product overview

FabRx is a pharmaceutical technology company offering the M3DIMAKER ecosystem, a unified platform comprising hardware (M3DIMAKER 1 and M3DIMAKER 2 pharmaceutical 3D printers), software (M3DIMAKER Studio and Hub & Spoke), and quality control accessories (Near Infrared Sensor, Pressure Sensor, Balance, Traceability). The company provides four distinct manufacturing technologies under one ecosystem: 3D Printing, Blister Filling, Capsule Filling, and Suppositories Filling. Supporting services include Pharma-ink Development for formulation optimization, AI-powered tools (M3DISEEN for printability prediction, M3DIFEEDBACK for patient feedback), and exchangeable printhead systems (SSE, FDM, DPE) for the M3DIMAKER 2. All products are GMP compliant and designed for personalized medicine production in pharmacies, hospitals, and clinical trial settings.

Differentiator

Problem solved

Functional benefit

Brands

  • M3DIMAKER: Pharmaceutical 3D printing ecosystem for personalized medicine production including M3DIMAKER 1 (single printhead) and M3DIMAKER 2 (multi-printhead) systems.
  • M3DIMAKER Studio
  • M3DIFEEDBACK
  • M3DISEEN
  • Pharma-ink

Products and services

  • M3DIMAKER 1 Single printhead, GMP-compliant pharmaceutical 3D printer for research and small-batch manufacture of personalized medicines and medical devices for human and veterinary precision medicine and drug development. Available by monthly subscription (from €1,999/month) targeting European pharmacies and hospitals.
  • M3DIMAKER 2 Multi-printhead (3 printhead attachments) GMP-compliant pharmaceutical 3D printer capable of rapid polypill manufacture and higher-throughput, larger batch production of personalized medicines and medical devices. Targeted at pharmaceutical companies, CDMOs, and large research institutions.
  • M3DIMAKER Studio Software Bespoke software developed by FABRX·AI that controls the M3DIMAKER ecosystem, enabling 3D model selection, parameter preparation, and printer control. Includes dose-library generator and user group management; protocols can be locked for quality assurance in clinical use, and Hub & Spoke capabilities add secure VPN access, protocol sharing, downloadable libraries, and performance reports.
  • M3DISEEN AI-driven predicting tool that assesses 3D printability of pharmaceutical formulations. Takes drug, excipients, and proportions as input, predicts formulation printability, and provides recommended 3D printing parameters and dissolution insights. Currently focused on FDM and offered as an online tool.
  • M3DIFEEDBACK Phone application designed to collect patient and carer feedback for clinical projects. Custom downloadable apps can be created for each clinical project to provide a user-friendly feedback experience.
  • Pharma-ink Development Services Professional formulation development services ranging from consultation to full formulation development and analysis, including active ingredient characterization, 3D printing optimization, in vitro analysis, and small batch manufacture with clinical trial guidance. Helps customers develop and optimize 3D-printable pharmaceutical formulations.
  • FABRX Syringe Preheater Hardware accessory introduced in January 2026 for the M3DIMAKER ecosystem, designed to revolutionize high-volume 3D printing applications by preheating syringes used in pharmaceutical 3D printing.

Quantifiable outcome

  • Auto-filling 10,000 capsules with personalized doses in one day

Companies that use FabRx

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles4 records

FabRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature14 records

FabRx partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Pete PharmacoreStrategic or Co-development Partner · 1 September 2025Strategic partnership to introduce pharmaceutical 3D printing technology to the U.S. compounding pharmacy market. Pete Pharma developed a pharmacy-first business model to reduce operational burden and improve workflow efficiency for independent pharmacies. The partnership combines Pete Pharma's market expertise with FabRx's M3DIMAKER technology (M3DIMAKER 1 for research and small-batch manufacturing, M3DIMAKER 2 for higher throughput) to modernize personalized medicine production through automation and enhanced customization capabilities.
  • University College London (UCL)coreStrategic or Co-development PartnerFounding research institution and origin of FabRx technology. Co-founders Prof. Alvaro Goyanes and colleagues developed pharmaceutical 3D printing technology at UCL. Ongoing collaboration for research and development of personalized medicine solutions.
  • FABRX·AIcoreTechnology or IntegrationSubsidiary company launched in 2023 in Spain, focused on advanced software solutions for pharmaceutical 3D printing and automated drug dispensing. Develops M3DIMAKER Studio software, M3DIFEEDBACK app, and M3DISEEN AI prediction tool.
  • PfizerminorStrategic or Co-development PartnerPharmaceutical company collaboration for personalized medicine development research.
  • AstraZenecaminorStrategic or Co-development PartnerPharmaceutical company collaboration for personalized medicine research.
  • Vall d'Hebron University HospitalminorStrategic or Co-development PartnerClinical collaboration for pharmaceutical 3D printing applications in hospital pharmacy settings, including pediatric formulations.
  • Great Ormond Street HospitalminorStrategic or Co-development PartnerPediatric healthcare institution collaboration for child-friendly personalized medicines using 3D printing technology.
  • Gustave RoussyminorStrategic or Co-development PartnerCancer research center collaboration for pharmaceutical 3D printing applications in oncology treatments.

Scale indicators2 records

Recent moves8 records

Expansion highlights6 records

FabRx competitors and assessment

Company assessment

Direct peers

  • Triastek: Triastek is a Chinese pharmaceutical 3D printing company developing 3D-printed drug formulations and working with regulators (including FDA IND clearances). It is the most comparable direct competitor to FabRx in pharmaceutical 3D printing hardware and formulation services.
  • Aprecia Pharmaceuticals: Aprecia is the pioneer of pharmaceutical 3D printing, holding the first FDA-approved 3D-printed drug (Spritam). Its ZipDose platform competes directly with FabRx's M3DIMAKER in producing personalized oral dosage forms for hospitals and pharmacies.
  • MB Therapeutics (formerly DiHeSys): MB Therapeutics is a German pharmaceutical 3D printing startup focused on personalized medicine and printing of individualized dosage forms. It is a direct European competitor in pharmaceutical 3D printing technology.
  • Laxxon Medical: Laxxon Medical develops 3D-printed pharmaceuticals with its SPID-Technology platform, focused on oral drug delivery and personalized dosing. Comparable to FabRx in target market (personalized oral dosage forms) and technology category.

Emerging players

  • Inventia Healthcare: Inventia develops powder-based pharmaceutical 3D printing technology for personalized medicine and clinical/research applications. Comparable as an emerging specialist in pharma 3D printing but with narrower scope than FabRx's multi-technology platform.

Broad incumbents

  • Catalent: Catalent is a major CDMO with capabilities in oral solid dose manufacturing and is exploring advanced drug delivery technologies. As a broad incumbent in pharma manufacturing services, it represents the consolidation target or large competitor FabRx may eventually compete against for hospital compounding contracts.
  • GEA Pharma & Healthcare: GEA supplies industrial processing equipment for pharmaceutical manufacturing, including equipment for solid dosage forms. As an industrial incumbent in pharma manufacturing equipment, it could enter the personalized 3D printing space and compete with FabRx for hospital pharmacy installations.
  • Glatt Group: Glatt offers integrated solutions for pharmaceutical production including solid dosage form manufacturing equipment. It is comparable to FabRx as a provider of equipment used in pharmaceutical production, though with a much broader and more established industrial equipment portfolio.
  • Thermo Fisher Scientific (Patheon/CDMO): Through its Patheon CDMO business, Thermo Fisher offers pharmaceutical development and manufacturing services including oral solid dose capabilities. As a broad incumbent in pharma services, it competes for hospital and CDMO contracts that FabRx's platform could also address.

Others

  • Evonik Industries: Evonik is a global specialty chemicals company and supplier of pharmaceutical excipients, including materials used in 3D-printed drug formulations. It is a partner of FabRx (excipient supplier) and thematically adjacent as the materials backbone of pharmaceutical 3D printing ecosystems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

FabRx social profiles

Digital presence

FabRx compliance and trust

Trust signal

Compliance1 record

FabRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FabRx leadership team

Management profile

Number of profiles

Profiles11 records

FabRx subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

FabRx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FabRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FabRx

What does FabRx do?

FabRx develops and commercializes the M3DIMAKER ecosystem of GMP-compliant pharmaceutical 3D printers (single-printhead M3DIMAKER 1 and multi-printhead M3DIMAKER 2), control software, in-line quality control sensors, and Pharma-ink formulation services that enable pharmacies, hospitals, and pharmaceutical companies to produce personalized medicines and small-batch pharmaceuticals on-site. The platform supports multiple manufacturing modalities including 3D printing, blister filling, capsule filling, and suppository filling under a single integrated system.

Is FabRx a public or private company?

FabRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was FabRx founded?

FabRx was founded in 2014. It employs 11 to 50 people.

Where is FabRx based?

FabRx is headquartered in London, United Kingdom, in the Europe region.

How does FabRx make money?

Four revenue lines are on record. Pharmaceutical 3D Printer Sales are the primary driver. The others are printer Subscription, software Licensing and pharma-ink Development Services.

Who are FabRx's main competitors?

Direct peers on record are Triastek, Aprecia Pharmaceuticals, MB Therapeutics (formerly DiHeSys) and Laxxon Medical. Inventia Healthcare is listed as an emerging player. Broad incumbents are Catalent, GEA Pharma & Healthcare, Glatt Group and Thermo Fisher Scientific (Patheon/CDMO). Evonik Industries is listed as an others.

Does FabRx have an API?

No public API is recorded for FabRx.

What industry is FabRx in?

FabRx's product category is Pharmaceutical 3D Printing Systems. Its primary akta.pro industry code is HLACAKAM, Compounding Pharmacy & Sterile Prep Workflow Systems, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 3231 and its SIC code is 3555.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Towards HealthcareU.S. Compounding Pharmacy Market to Push USD 12.79 Bn by 2035The U.S. compounding pharmacy market generated $6.98 billion in revenue in 2025 and is projected to reach $12.79 billion by 2035, growing at a compound annual growth rate of 6.24% through 2035. Key growth drivers include rising demand for personalized medications, increasing prevalence of chronic diseases, an aging population, ongoing drug shortages, and regulatory support under the Drug Quality and Security Act. Major industry developments in 2025 include Revelation Pharma's acquisition of Cascade Specialty Pharmacy, Empower Pharmacy's recognition on the Inc. 5000 list, and collaborations such as the partnership between Pete Pharma and FABRX to introduce pharmaceutical 3D printing to the U.S. compounding market.3DHealsEpisode 112: Automating Compounding Pharmacies with FabRx 3D PrintingThis podcast episode features Prof. Alvaro Goyanes, co-founder and CEO of FabRx, discussing the company's 3D printing technology for personalized medicine fabrication at UCL in London. Key topics include clinical partnerships and US expansion through Pete Pharma, quality control systems for the M3DIMAKER printer, and research applications spanning HRT, hydrocortisol, cancer treatments, and pediatric sickle cell medications. The episode also covers regulatory developments including UK Point-of-Care Manufacturing Regulation and EMA's Q&A document on 3D printing.Fortunebusinessinsights3D Printed Drugs Market Size, Share, Growth Report, 2034The global 3D printed drugs market was valued at USD 140.6 billion in 2025 and is projected to reach USD 496.95 billion by 2034, growing at a CAGR of 15.06% during the forecast period 2026–2034. Key market drivers include rising demand for personalized medicine, FDA approval of products such as Spritam (levetiracetam), and technological advances in 3D printing techniques including inkjet printing, selective laser sintering, and melt extrusion deposition. North America currently leads the market, while the Asia-Pacific region is expected to experience the fastest growth, with key players including Aprecia Pharmaceutical, TRIASTEK, and FabRx Ltd.Towards HealthcareU.S. Compounding Pharmacy Top Companies and Strategic InvolvementsThe U.S. compounding pharmacy market was valued at $6.57 billion in 2024 and is projected to reach $12.02 billion by 2034, driven by a 6.24% CAGR. Key recent developments include Eli Lilly's February 2025 launch of Zepbound single-dose vials through its LillyDirect Self Pay Pharmacy Solutions program at $499, and LifeMD's May 2025 announcement of a $299 introductory bundle for Wegovy patients in partnership with Novo Nordisk. In September 2025, Pete Pharma announced a collaboration with pharmaceutical 3D printing leader FABRX to introduce cutting-edge compounding technology to the U.S. market.HLTHPete Pharma and Fabrx Partner to Revolutionize U.S. Compounding Pharmacy with 3D PrintingPete Pharma announced a strategic partnership with Fabrx to introduce pharmaceutical 3D printing technology to the U.S. compounding pharmacy market, aiming to modernize personalized medicine production through automation and enhanced customization capabilities. Fabrx provides two systems—the M3DIMAKER 1 for research and small-batch manufacturing, and the more advanced M3DIMAKER 2 with multiple printheads for higher throughput—supporting applications across pediatrics, hormone replacement therapy, and metabolic care. Pete Pharma has developed a pharmacy-first business model designed to reduce operational burden and improve workflow efficiency for independent pharmacies, positioning the partnership to address critical challenges in the compounding pharmacy sector.PharmiWeb.comA Pharmacy-First Approach to Innovation: Pete Pharma and FABRX Announce PartnershipPete Pharma announced a partnership with FABRX to introduce pharmaceutical 3D printing to the U.S. compounding pharmacy market. The collaboration aims to improve workflow efficiency, enable medication personalization, and enhance quality control. Pete Pharma will launch the platform through a pharmacy-first business model.YahooA Pharmacy-First Approach to Innovation: Pete Pharma and FABRX Announce PartnershipPete Pharma announced a partnership with FABRX to introduce pharmaceutical 3D printing to U.S. compounding pharmacies. The collaboration aims to improve workflow efficiency, enable medication personalization, and enhance quality control. Pete Pharma will launch the platform through a pharmacy-first, scalable business model.YahooA Pharmacy-First Approach to Innovation: Pete Pharma and FABRX Announce PartnershipPete Pharma announced a partnership with FABRX to introduce pharmaceutical 3D printing to U.S. compounding pharmacies. The collaboration aims to improve workflow efficiency, enable medication personalization, and enhance quality control. Pete Pharma will launch the platform through a pharmacy-first business model.Business Wire BlogA Pharmacy-First Approach to Innovation: Pete Pharma and FABRX Announce PartnershipPete Pharma announced a partnership with FABRX to bring pharmaceutical 3D printing to U.S. compounding pharmacies. The collaboration aims to improve workflow efficiency, enable medication personalization, and enhance quality control. Pete Pharma will launch the platform through a pharmacy-first business model.LinkedInThe 10 Trends Shaping the Future of PharmaAn article outlines ten trends reshaping the pharmaceutical industry, including patient advisory boards, digital health strategies tied to drugs, ingestible digital pills, in silico trials, virtual reality for pain relief, pharmacogenomics, 3D-printed drugs, AI in drug development, updated FDA regulations, and augmented reality for drug descriptions. It cites examples such as Roche's acquisition of mySugr, FDA-approved digital pills, and FabRx's projected 5-10 year commercialization of printed tablets.